Harnessing the Immune System to Fight Disease

Broad Immunotherapy Reach


Advancing first-in-class immunotherapy product candidates in oncology, as well as infectious and allergic diseases.



Next-generation, productive ZVex® and GLAAS™ discovery engines are the source of multiple product candidates across several therapeutic areas.


We leverage our cutting-edge platforms to produce product candidates and utilize distinct therapeutic approaches that, we believe, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action. Our two primary product candidates, CMB305 and G100, are currently in multiple Phase 1 and 2 clinical trials.
Read More

Infectious and allergic DISEASES

ZVex® and GLAAS™ -based products have potential therapeutic utility outside of oncology, as well, and provide an opportunity for an innovative approach to develop improved therapeutics. We have been successfully executing a strategy to partner individual indications outside of oncology in infectious and allergic diseases, which provide potential downstream economics while preserving growth opportunity in the future.
(see partners)
Read More

Latest News